Paraplatin Alternatives Compared
| Paraplatin | Elahere | Carboplatin |
|
|---|
| Paraplatin (carboplatin) | Elahere (mirvetuximab soravtansine) | Carboplatin |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Ovarian Cancer, Cancer, Cervical Cancer. Paraplatin may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer. Elahere may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Ovarian Cancer, Cancer, Cervical Cancer. carboplatin may also be used for purposes not listed in this medication guide. |
Related suggestions Ovarian Cancer
|
|||||||||||||||||||||||
| More about Paraplatin (carboplatin) | More about Elahere (mirvetuximab soravtansine) | More about Carboplatin | ||||||||||||||||||||||||
| Generic Status | ||||||||||||||||||||||||||
|
No lower-cost generic available |
||||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Paraplatin has an average rating of 9.0 out of 10 from a total of 2 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Elahere has an average rating of 8.0 out of 10 from a total of 3 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Carboplatin has an average rating of 6.3 out of 10 from a total of 4 ratings on Drugs.com. 67% of reviewers reported a positive effect, while 33% reported a negative effect. |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Side Effects | ||||||||||||||||||||||||||
|
Common side effects include:
See also: Paraplatin side effects in more detail. |
See also: Elahere side effects in more detail. |
Commonly reported side effects include:
See also: carboplatin side effects in more detail. |
||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Paraplatin prices and generic prices |
View all Elahere prices |
View all carboplatin prices |
||||||||||||||||||||||||
| Dosage Form(s) Available | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Other carboplatin brands include: Carboplatin Novaplus |
N/A |
Carboplatin Novaplus | ||||||||||||||||||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||||||||||
|
120 hours |
115.2 hours |
120 hours |
||||||||||||||||||||||||
| CSA Schedule ** View glossary of terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 333 drugs are known to interact with Paraplatin:
|
A total of 115 drugs are known to interact with Elahere:
|
A total of 333 drugs are known to interact with carboplatin:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
March 03, 1989 |
November 14, 2022 |
N/A |
||||||||||||||||||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.